Michelle M. White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle M. White has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Emer Patricia Reeves
Royal College of Surgeons in Ireland Dublin, Ireland
6 shared publications Noel G. McElvaney
Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
6 shared publications- Cormac McCarthy
School of Medicine, University College Dublin, Dublin, Ireland
4 shared publications Kerstin Pohl
Respiratory Research Division, Royal College of Surgeons in Ireland, ERC Beaumont Hospital, Dublin 9, Ireland
3 shared publicationsOliver J. McElvaney
Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
3 shared publicationsDavid A. Bergin
Respiratory Research Division, Royal College of Surgeons in Ireland, ERC Beaumont Hospital, Dublin 9, Ireland
2 shared publications
Latest Publications
- Open Access
- 1 September 2017
- Published by Elsevier in EBioMedicine
- Vol. 23, 173-184
Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
- 1 September 2017
- Published by Elsevier in EBioMedicine
- Vol. 23, 173-184
Open AccessNeutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
- Open Access
- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-14
Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The resultant characteristic ion transport defect results in decreased mucociliary clearance, bacterial colonisation, and chronic neutrophil-dominated inflammation. Much knowledge surrounding the pathophysiology of the disease has been gained through the generation of animal models, despite inherent limitations in each. The failure of certain mouse models to recapitulate the phenotypic manifestations of human disease has initiated the generation of larger animals in which to study CF, including the pig and the ferret. This review will summarise the basic phenotypes of three animal models and describe the contributions of such animal studies to our current understanding of CF.
- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-14
Open AccessAnimal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The resultant characteristic ion transport defect results in decreased mucociliary clearance, bacterial colonisation, and chronic neutrophil-dominated inflammation. Much knowledge surrounding the pathophysiology of the disease has been gained through the generation of animal models, despite inherent limitations in each. The failure of certain mouse models to recapitulate the phenotypic manifestations of human disease has initiated the generation of larger animals in which to study CF, including the pig and the ferret. This review will summarise the basic phenotypes of three animal models and describe the contributions of such animal studies to our current understanding of CF.
- 15 October 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 195 (8) , 3628-3641
The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling
Leukotriene B4 (LTB4) contributes to many inflammatory diseases, including genetic and nongenetic forms of chronic obstructive pulmonary disease. α-1 Antitrypsin (AAT) deficiency (AATD) is characterized by destruction of lung parenchyma and development of emphysema, caused by low AAT levels and a high neutrophil burden in the airways of affected individuals. In this study we assessed whether AATD is an LTB4-related disease and investigated the ability of serum AAT to control LTB4 signaling in neutrophils. In vitro studies demonstrate that neutrophil elastase is a key player in the LTB4 inflammatory cycle in AATD, causing increased LTB4 production, and associated BLT1 membrane receptor expression. AATD patients homozygous for the Z allele were characterized by increased neutrophil adhesion and degranulation responses to LTB4. We demonstrate that AAT can bind LTB4 and that AAT/LTB4 complex formation modulates BLT1 engagement and downstream signaling events, including 1,4,5-triphosphate production and Ca2+ flux. Additionally, treatment of ZZ-AATD individuals with AAT augmentation therapy decreased plasma LTB4 concentrations and reduced levels of membrane-bound neutrophil elastase. Collectively, these results provide a mechanism by which AAT augmentation therapy impacts on LTB4 signaling in vivo, and not only reinforces the utility of this therapy for resolving inflammation in AATD, but supports useful future clinical applications in treatment of other LTB4-related diseases.
- 15 October 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 195 (8) , 3628-3641
The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling
Leukotriene B4 (LTB4) contributes to many inflammatory diseases, including genetic and nongenetic forms of chronic obstructive pulmonary disease. α-1 Antitrypsin (AAT) deficiency (AATD) is characterized by destruction of lung parenchyma and development of emphysema, caused by low AAT levels and a high neutrophil burden in the airways of affected individuals. In this study we assessed whether AATD is an LTB4-related disease and investigated the ability of serum AAT to control LTB4 signaling in neutrophils. In vitro studies demonstrate that neutrophil elastase is a key player in the LTB4 inflammatory cycle in AATD, causing increased LTB4 production, and associated BLT1 membrane receptor expression. AATD patients homozygous for the Z allele were characterized by increased neutrophil adhesion and degranulation responses to LTB4. We demonstrate that AAT can bind LTB4 and that AAT/LTB4 complex formation modulates BLT1 engagement and downstream signaling events, including 1,4,5-triphosphate production and Ca2+ flux. Additionally, treatment of ZZ-AATD individuals with AAT augmentation therapy decreased plasma LTB4 concentrations and reduced levels of membrane-bound neutrophil elastase. Collectively, these results provide a mechanism by which AAT augmentation therapy impacts on LTB4 signaling in vivo, and not only reinforces the utility of this therapy for resolving inflammation in AATD, but supports useful future clinical applications in treatment of other LTB4-related diseases.
- Open Access
- 24 August 2015
- Published by IntechOpen
New Research on the Importance of Cystic Fibrosis Transmembrane Conductance Regulator Function for Optimal Neutrophil Activity
New Research on the Importance of Cystic Fibrosis Transmembrane Conductance Regulator Function for Optimal Neutrophil Activity | InTechOpen, Published on: 2015-08-24. Authors: Michelle M. White, Fatma Gargoum, Niall Browne, et
- 24 August 2015
- Published by IntechOpen
Open AccessNew Research on the Importance of Cystic Fibrosis Transmembrane Conductance Regulator Function for Optimal Neutrophil Activity
New Research on the Importance of Cystic Fibrosis Transmembrane Conductance Regulator Function for Optimal Neutrophil Activity | InTechOpen, Published on: 2015-08-24. Authors: Michelle M. White, Fatma Gargoum, Niall Browne, et
- 1 February 2015
- Published by Elsevier in Molecular Immunology
- Vol. 63 (2) , 550-558
The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis
- 1 February 2015
- Published by Elsevier in Molecular Immunology
- Vol. 63 (2) , 550-558
The effect of the decoy molecule PA401 on CXCL8 levels in bronchoalveolar lavage fluid of patients with cystic fibrosis
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 4 (3) , 179-191
Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function
Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Critical Care Medicine
- Vol. 4 (3) , 179-191
Open AccessInhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function
Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function
- Open Access
- 14 August 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (7) , 999-1009
A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
Key Points: In people with cystic fibrosis, defective CFTR function alters neutrophil cytosolic ion homeostasis leading to impaired degranulation. By normalizing CFTR function, ivacaftor treatment corrects neutrophil degranulation resulting in normalized killing of bacteria.
- 14 August 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (7) , 999-1009
Open AccessA neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
Key Points: In people with cystic fibrosis, defective CFTR function alters neutrophil cytosolic ion homeostasis leading to impaired degranulation. By normalizing CFTR function, ivacaftor treatment corrects neutrophil degranulation resulting in normalized killing of bacteria.